Prognosis
J&J Shot’s Future Depends on 15 Cautious Vaccine Experts
- Age, gender restrictions possible recipe for shot’s resumption
- Panel meeting Friday seeks more data on rare blood clots
This article is for subscribers only.
Advisers to the Centers for Disease Control and Prevention are under pressure to decide whether the U.S. can resume use of Johnson & Johnson’s Covid-19 vaccine, perhaps with some limits, 10 days into a pause on using it.
Members of CDC’s Advisory Committee on Immunization Practices will reconvene Friday to decide whether they have enough data to say who should -- or shouldn’t -- receive J&J’s shot. Options include a full resumption, restrictions by age or gender, or extending the pause.
Wilbur Chen, a voting member of the committee and a professor at the University of Maryland School of Medicine, said he would like to see the vaccine used.